A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors. (4th October 2021)

• Record Type: Journal Article
• Authors: Oza, Amit M.; Dubois, François; Hegg, Roberto; Hernández, Carlos Alberto; Finocchiaro, Gaetano; Ghiringhelli, François; Zamagni, Claudio; Nick, Sonja; Irahara, Natsumi; Perretti, Thomas; Colombo, Nicoletta
• Is Part Of: Oncologist. Volume 26:Number 12(2021)
• Page Start: e2254
• Page End: e2264
• Publication Date: 2021-10-04
• Subjects: Bevacizumab -- Cancer -- Long‐term treatment -- Safety -- Solid tumor; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1002/onco.13971
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Background: Bevacizumab has been studied in numerous clinical trials in multiple types of cancer; however, patients may receive bevacizumab over an extended period of time. This study assessed the long‐term safety and tolerability of bevacizumab among patients with solid tumors. Materials and Methods: Patients enrolled in a Roche/Genentech‐sponsored trial who had derived benefit from bevacizumab therapy as monotherapy or in combination with anticancer drugs were eligible for continuation of bevacizumab in this long‐term extension (LTE) study. The primary endpoints were the incidence of adverse events (AEs) of Common Terminology Criteria for AEs (CTCAE) grade ≥3 related to bevacizumab treatment, serious AEs (SAEs), and deaths. Results: Ninety‐five patients with the following cancer types were enrolled in the LTE: ovarian cancer or peritoneal carcinoma ( n = 41), non‐small cell lung cancer ( n = 16), glioblastoma multiforme ( n = 14), breast cancer ( n = 11), colorectal cancer ( n = 7), or renal cell carcinoma ( n = 6). The median (range) duration of bevacizumab treatment was 15.6 (0.0–81.0) months during the LTE and 57.5 (16.4–134.9) months overall (parent trial + LTE), with three patients receiving bevacizumab for >10 years. Overall, 17 patients (17.9%) experienced SAEs, and 21 (22.1%) had a bevacizumab‐related AE of CTCAE grade ≥3 (proteinuria and hypertension were the most common). Four patients died: three from disease progression and one from an AE considered unrelated to bevacizumab. Conclusion: The safety outcomes observed support the tolerability of long‐term bevacizumab in patients with various solid tumors, with a median extended treatment duration of almost 5 years overall and >10 years in some individual patients. ClinicalTrials.gov identifier: NCT01588184. Implications for Practice: In this long‐term extension study of patients with solid tumors, the median duration of bevacizumab treatment (including parent trials) was just under 5 years, with a long‐term exposure in some patients of 7 to >10 years. Grade ≥3 adverse events related to bevacizumab were consistent with the established safety profile, with proteinuria and hypertension being the most common. Patients received bevacizumab over an extended period of time (beyond the length of most clinical trials), and the overall safety outcomes observed support the tolerability of long‐term bevacizumab treatment in patients with solid tumors, with clinical benefit achieved over an extended period. Abstract : This article assesses the safety and tolerability of long‐term administration of bevacizumab among patients with solid tumors.